pubmed-article:15075540 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15075540 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
pubmed-article:15075540 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:15075540 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:15075540 | lifeskim:mentions | umls-concept:C0040077 | lld:lifeskim |
pubmed-article:15075540 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
pubmed-article:15075540 | lifeskim:mentions | umls-concept:C0887947 | lld:lifeskim |
pubmed-article:15075540 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:15075540 | pubmed:dateCreated | 2004-4-12 | lld:pubmed |
pubmed-article:15075540 | pubmed:abstractText | To investigate the impact of 215 HIV-1 revertants on the risk of virological failure of the first thymidine analog-containing highly active antiretroviral therapy (HAART). | lld:pubmed |
pubmed-article:15075540 | pubmed:language | eng | lld:pubmed |
pubmed-article:15075540 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15075540 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15075540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15075540 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15075540 | pubmed:month | Jan | lld:pubmed |
pubmed-article:15075540 | pubmed:issn | 0269-9370 | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:BerrierJJ | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:d'Arminio... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:MoroniMauroM | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:ChiodoFrances... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:GhinelliFlori... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:Cozzi-LepriAl... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:PernoCarlo... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:BalottaClaudi... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:ViolinMichela... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:VellecaRossel... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:VincentiAnton... | lld:pubmed |
pubmed-article:15075540 | pubmed:author | pubmed-author:D'EliaSalvato... | lld:pubmed |
pubmed-article:15075540 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15075540 | pubmed:day | 23 | lld:pubmed |
pubmed-article:15075540 | pubmed:volume | 18 | lld:pubmed |
pubmed-article:15075540 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15075540 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15075540 | pubmed:pagination | 227-35 | lld:pubmed |
pubmed-article:15075540 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:meshHeading | pubmed-meshheading:15075540... | lld:pubmed |
pubmed-article:15075540 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:15075540 | pubmed:articleTitle | Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. | lld:pubmed |
pubmed-article:15075540 | pubmed:affiliation | Institute of Infectious and Tropical Diseases, University of Milan, Italy. | lld:pubmed |
pubmed-article:15075540 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15075540 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:15075540 | pubmed:publicationType | Multicenter Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15075540 | lld:pubmed |